Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial
- PMID: 18714059
- DOI: 10.1001/jama.300.7.795
Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial
Abstract
Context: Observational studies have reported associations between circulating total homocysteine concentration and risk of cardiovascular disease. Oral administration of folic acid and vitamin B(12) can lower plasma total homocysteine levels.
Objective: To assess the effect of treatment with folic acid and vitamin B(12) and the effect of treatment with vitamin B(6) as secondary prevention in patients with coronary artery disease or aortic valve stenosis.
Design, setting, and participants: Randomized, double-blind controlled trial conducted in the 2 university hospitals in western Norway in 1999-2006. A total of 3096 adult participants undergoing coronary angiography (20.5% female; mean age, 61.7 years) were randomized. At baseline, 59.3% had double- or triple-vessel disease, 83.7% had stable angina pectoris, and 14.9% had acute coronary syndromes.
Interventions: Using a 2 x 2 factorial design, participants were randomly assigned to 1 of 4 groups receiving daily oral treatment with folic acid, 0.8 mg, plus vitamin B(12), 0.4 mg, plus vitamin B(6), 40 mg (n = 772); folic acid plus vitamin B(12) (n = 772); vitamin B(6) alone (n = 772); or placebo (n = 780).
Main outcome measures: The primary end point was a composite of all-cause death, nonfatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and nonfatal thromboembolic stroke.
Results: Mean plasma total homocysteine concentration was reduced by 30% after 1 year of treatment in the groups receiving folic acid and vitamin B(12). The trial was terminated early because of concern among participants due to preliminary results from a contemporaneous Norwegian trial suggesting adverse effects from the intervention. During a median 38 months of follow-up, the primary end point was experienced by a total of 422 participants (13.7%): 219 participants (14.2%) receiving folic acid/vitamin B(12) vs 203 (13.1%) not receiving such treatment (hazard ratio, 1.09; 95% confidence interval, 0.90-1.32; P = .36) and 200 participants (13.0%) receiving vitamin B(6) vs 222 (14.3%) not receiving vitamin B(6) (hazard ratio, 0.90; 95% confidence interval, 0.74-1.09; P = .28).
Conclusions: This trial did not find an effect of treatment with folic acid/vitamin B(12) or vitamin B(6) on total mortality or cardiovascular events. Our findings do not support the use of B vitamins as secondary prevention in patients with coronary artery disease.
Trial registration: clinicaltrials.gov Identifier: NCT00354081.
Comment in
-
Lowering homocysteine with B vitamins in patients with coronary artery disease.JAMA. 2008 Dec 24;300(24):2852-3; author reply 2853-4. doi: 10.1001/jama.2008.836. JAMA. 2008. PMID: 19109109 No abstract available.
-
Lowering homocysteine with B vitamins in patients with coronary artery disease.JAMA. 2008 Dec 24;300(24):2852; author reply 2853-4. doi: 10.1001/jama.2008.835. JAMA. 2008. PMID: 19109110 No abstract available.
-
Lowering homocysteine with B vitamins in patients with coronary artery disease.JAMA. 2008 Dec 24;300(24):2853; author reply 2853-4. doi: 10.1001/jama.2008.837. JAMA. 2008. PMID: 19109111 No abstract available.
Similar articles
-
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.JAMA. 2007 Sep 12;298(10):1163-70. doi: 10.1001/jama.298.10.1163. JAMA. 2007. PMID: 17848650 Clinical Trial.
-
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.JAMA. 2004 Feb 4;291(5):565-75. doi: 10.1001/jama.291.5.565. JAMA. 2004. PMID: 14762035 Clinical Trial.
-
Cancer incidence and mortality after treatment with folic acid and vitamin B12.JAMA. 2009 Nov 18;302(19):2119-26. doi: 10.1001/jama.2009.1622. JAMA. 2009. PMID: 19920236
-
Homocysteine-lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article. Review.
-
Interventions for lowering plasma homocysteine levels in dialysis patients.Cochrane Database Syst Rev. 2016 May 31;2016(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Cochrane Database Syst Rev. 2016. PMID: 27243372 Free PMC article. Review.
Cited by
-
What Causes Premature Coronary Artery Disease?Curr Atheroscler Rep. 2024 Jun;26(6):189-203. doi: 10.1007/s11883-024-01200-y. Epub 2024 Apr 4. Curr Atheroscler Rep. 2024. PMID: 38573470 Review.
-
Association between dietary macronutrient composition and plasma one-carbon metabolites and B-vitamin cofactors in patients with stable angina pectoris.Br J Nutr. 2024 May 28;131(10):1678-1690. doi: 10.1017/S0007114524000473. Epub 2024 Feb 16. Br J Nutr. 2024. PMID: 38361451 Free PMC article.
-
B-vitamin Treatment Modifies the Mortality Risk Associated with Calcium Channel Blockers in Patients with Suspected Stable Angina Pectoris: A Prospective Cohort Study.Am J Clin Nutr. 2023 Jul;118(1):77-84. doi: 10.1016/j.ajcnut.2023.04.033. Epub 2023 Apr 28. Am J Clin Nutr. 2023. PMID: 37121550 Free PMC article. Clinical Trial.
-
Kynurenine Pathway Metabolites in the Blood and Cerebrospinal Fluid Are Associated with Human Aging.Oxid Med Cell Longev. 2022 Oct 21;2022:5019752. doi: 10.1155/2022/5019752. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 36312896 Free PMC article.
-
Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease.PLoS One. 2022 Oct 27;17(10):e0275956. doi: 10.1371/journal.pone.0275956. eCollection 2022. PLoS One. 2022. PMID: 36301961 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical